MK-677 Ghrelin Agonist: Oral GH Secretagogue, Efficacy & Long-Term Safety Unknowns

MK-677 (ibutamoren mesylate) is a non-peptide, orally bioavailable agonist at the ghrelin receptor (GHSR-1a). Unlike injectable GH secretagogue peptides like ipamorelin, MK-677 is a small molecule that survives first-pass metabolism and oral administration — making it exceptionally rare in the GH-axis research space. It was developed by Merck and advanced through Phase II/III clinical trials for muscle wasting, frailty, and growth hormone deficiency before development was ultimately discontinued.

Oral Bioavailability: Why This Is Unusual

Most compounds that activate peptide receptors are themselves peptides — and peptides are destroyed by GI proteases before reaching systemic circulation in meaningful quantities. MK-677’s non-peptide structure allows it to reach the bloodstream after oral ingestion with approximately 60–70% bioavailability (based on Phase I data). Oral dosing at 25 mg once daily robustly increases pulsatile GH secretion and sustains IGF-1 elevation for 24 hours. This single daily oral dose replaces what would otherwise require multiple daily subcutaneous injections.

GH and IGF-1 Elevation: Clinical Data

The GAIT trial (Nass et al., 2008, Ann Intern Med) evaluated MK-677 25 mg/day for 2 years in healthy elderly subjects (65+ years). Key findings: GH and IGF-1 increased significantly and were maintained throughout the 2-year study. Lean body mass increased. Fat mass was not significantly reduced. Muscle strength improvements were not statistically significant vs. placebo. The SHIP trial (Svensson et al., 2001) in young, obese males demonstrated that MK-677 improved nitrogen balance (an index of protein retention) at 25 mg/day.

A Phase III trial (Adunsky et al., 2011) tested MK-677 in hip fracture rehabilitation patients over 24 weeks. MK-677 was associated with improved functional outcomes in a post-hoc analysis but failed its pre-specified primary endpoint, contributing to the discontinuation of the development program.

Water Retention: The Most Common Side Effect

Water retention and edema are the most consistently reported adverse effects in MK-677 clinical trials. GH stimulates sodium and water reabsorption by the kidney. In the GAIT trial, edema occurred in 11.5% of the MK-677 group vs. 4.8% in placebo. Some degree of water retention (perceived as “puffiness” or temporary weight increase of 1–3 kg) is experienced by most users of MK-677 at 25 mg/day. For lean-mass research, the retained weight is therefore not entirely lean tissue.

Insulin Sensitivity Trade-off

Elevated GH reduces insulin sensitivity (GH is a counter-regulatory hormone to insulin, opposing insulin action in peripheral tissues). In the GAIT trial, fasting blood glucose and insulin levels increased in the MK-677 group over 2 years, and 2 cases of frank diabetes were reported in the MK-677 arm vs. 0 in placebo (in a sample of ~65 subjects per arm — small numbers). Researchers using MK-677 should monitor fasting glucose periodically, particularly those with pre-existing insulin resistance or family history of type 2 diabetes.

Long-Term Safety Unknowns

The longest controlled human study of MK-677 is 2 years (GAIT trial). Beyond this window, safety is unknown. The primary theoretical concerns are: (1) IGF-1 elevation and theoretical oncogenesis risk — IGF-1 promotes cell proliferation and has been associated with certain cancers in epidemiological studies, though no clinical trial has demonstrated increased cancer incidence with MK-677; (2) cardiovascular effects — in the GAIT trial, there was a numerically higher rate of congestive heart failure in the MK-677 arm (5 vs. 1 case in placebo), though sample sizes preclude conclusions; (3) cortisol elevation — MK-677, unlike ipamorelin, does produce some cortisol elevation via ACTH, though less than GHRP-2.

MK-677 is not a SARM (selective androgen receptor modulator), is not a steroid, and does not suppress the hypothalamic-pituitary-gonadal (HPG) axis. It does not require post-cycle therapy (PCT) in the androgen sense. However, the GH/IGF-1 axis effects require time to normalize after discontinuation.

Typical Research Dosing and Timing

Clinical studies have used 10–50 mg/day, with 25 mg/day being the most common and best-studied dose. Community research protocols often use 10–25 mg once daily, taken at bedtime (to align the GH pulse with the natural nocturnal GH peak and minimize daytime GH-related insulin resistance). MK-677 has a half-life of approximately 24 hours, making once-daily dosing pharmacologically appropriate. Hunger stimulation — a ghrelin receptor effect — is a notable side effect; evening dosing allows users to sleep through the peak hunger window.